key: cord-0844320-1f31tact
authors: Chang, Chun; Zhang, Linlin; Dong, Fawu; Liang, Ying; Chen, Yahong; Shang, Ying; Abulikemu, Mairipaiti; Sun, Yongchang
title: Asthma control, self‐management, and healthcare access during the COVID‐19 epidemic in Beijing
date: 2020-09-30
journal: Allergy
DOI: 10.1111/all.14591
sha: c97b9379dfc076741da59c34feab4af3c1e55fe0
doc_id: 844320
cord_uid: 1f31tact

nan

4 weeks before the survey. According to the criteria of ACT scoring from GINA, asthma was classified as controlled in 89.3%, partly controlled in 6.2%, and uncontrolled in 4.5% of the patients. During this period, 24.7% of the patients visited a hospital or clinic for asthma, with a total of 74 visits; 14.9% (11/74) of which were due to exacerbation of asthma, while the remaining (63/74, 85.1%) were for regular prescription of asthma medications. Only 6 patients (3.4%) sought consultation online (Table 1) .

Notably, 25.6% (45/176) of the patients experienced exacerbation of asthma symptoms during the COVID-19 epidemic, but 75.6%

(34/45) of them did not see a doctor, because 67.6% (23/34) of the patients felt that they did not need to go to the hospital and took more medications by themselves, and the remaining 32.4% (11/34) worried about cross-infection of COVID-19 in the hospital. No patient reported that he/she did not see a doctor because he/she could not arrange an appointment. Eleven patients went to the hospital due to exacerbation, 81.8% (9/11) to the outpatient, while 18.2%

(2/11) to the emergency department (ED).

Of note, during the COVID-19 epidemic, 13.5% (24/178) of the patients had worried about insufficient maintenance medications, among whom 45.8% (11/24, 6.2% of the total sample) reduced medication dosing for this reason. After reducing medication dosing, 27.3% (3/11, 1.7% of the total sample) of them experienced asthma aggravation. Among patients who had their prescriptions refilled during the COVID-19 epidemic, 60.6% (40/66) chose to go to a hospital, 36.4% (24/66) to a nearby pharmacy, and 3.0% (2/66) chose to purchase online.

A hundred and five patients were receiving maintenance therapy, which was illustrated in Table 2 . ICS plus LABA was the most commonly used combination therapy, followed by ICS/LABA plus oral leukotriene modifiers.

Our survey found that, during the COVID-19 epidemic in Beijing, the majority of our asthma patients had their disease controlled as defined by GINA, and the percentage of controlled asthma was higher than that reported before the pandemic. A multicenter, retrospective, cross-sectional study in China indicated that less than one-third (28.7%) of the patients had controlled asthma, and the control rate in Beijing was 31.4%. 5 We speculate that the higher control rate of our patients might be due to social distancing and mandatory closure of places where exposure to asthma triggers may occur, stepped-up public hygiene measures, and the wearing of masks during the COVID-19 epidemic, thereby reducing contact with allergens and viruses. However, it needs to be noted that ACT is used to assess asthma control in the past 4 weeks and therefore could not reflect the status of disease control in the 3 months of the COVID-19 epidemic.

However, during the study period, a quarter of our patients experienced an exacerbation of asthma, and the percentage was higher than that reported in an earlier study which showed that the proportion of patients experiencing an asthma exacerbation in the previous year was 15.5%. 5 The lower prevalence of maintenance therapy, reduction of maintenance therapy, the pollen season, and worries on epidemic may explain the increased number of reported asthma exacerbations in our survey. The patients enrolled in our study had a higher rate of asthma exacerbation but lower rates of ED visit and hospitalization. It is not surprising to see that one-third of them worried about the risk of exposure to SARS-CoV-2 in the hospital, although most patients believed that their symptoms were not severe and could be relieved by self-management with medications.

In our survey, most of the patients took their prescribed asthma medications as usual, which was consistent with guideline recommendations. 1,2,4 Indeed, there is no evidence regarding whether currently available asthma treatments, including corticosteroids and bronchodilators, increase the susceptibility to or severity of COVID-19. 1 On the contrary, it may be more likely that a patient with asthma would have an exacerbation from other causes, including seasonal pollen exposure or a virus other than SARS-CoV-2 if they stopped regular use of indicated controller therapy. 6 An exacerbation may drive asthmatic patients to seek medical treatment, which would put them at increased risk of being exposed to SARS-CoV-2 during the current pandemic. 4 The use of telehealth in asthma treatment is recommended within a risk-stratified context of the SARS-CoV-2 pandemic. 4 However, in our interview, only a few patients used online consultation during the epidemic in Beijing. Patients with mild-to-moderate or well-controlled asthma were encouraged to use digital medical services. 7 Outpatient service should be prioritized for patients who have poorly controlled asthma, worsening asthma symptoms, or who have required dose escalations of asthma medications in the past several months' time. 4 Since our survey was cross-sectional, no definite conclusion can be drawn about the causal relationship between risk factors and uncontrolled asthma. The enrollment of study participants was largely dependent on patients' willingness to be surveyed.

These participants might be more compliant to therapy and have well-controlled asthma, which could result in selection bias, and therefore, the proportion of patients with poorly controlled disease might be underestimated. However, since the participants were enrolled from a tertiary hospital, it was also likely that the symptoms of these patients were more severe. Moreover, the study was carried out in winter and spring (from January 25 to April 25) when seasonal aeroallergens and other respiratory viruses were also prevalent, 8 which might be associated with higher asthma exacerbation.

In conclusion, our survey revealed the status of asthma control, exacerbations, self-management, and healthcare utilization in patients with asthma during the COVID-19 epidemic in Beijing. The results support the recommendation that patients continue taking their prescribed asthma medications as usual and maintain good asthma control during the ongoing pandemic. For containment of viral transmission, social distancing is being encouraged, but measures should be taken to mitigate the negative impact on asthma. 

Accessed May 9, 2020. 2. National Institute for Health and Care Excellence. COVID-19 rapid guideline: severe asthma

Clinical guide for the management of respiratory patients during the coronavirus pandemic

COVID-19: pandemic contingency planning for the allergy and immunology clinic

Evaluation of asthma control and patient's perception of asthma: findings and analysis of a nationwide questionnaire-based survey in

ARIA-EAACI statement on asthma and COVID-19

Coronavirus disease 2019 (COVID-19)/people who need extra precautions/people who are at higher risk/people with moderate to severe asthma

Seasonal risk factors for asthma exacerbations among inner-city children